The Kimberly-Clark/Kenvue transaction is one of the worst-received major merger deals in recent years. Investors wondered why ...

Irving-based Kimberly-Clark snaps up Tylenol maker Kenvue in a cash-and-stock blockbuster, uniting Kleenex, Huggies, and Band ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.

The recent publicity could allow the company to get a good deal on Kenvue, which makes Tylenol, Band-Aids, and other ...

The drama continued Monday with senior FDA leaders as more details emerged about former Center for Drug Evaluation and ...

Evercore also said Kimberly’s move expands its footprint into two stable, cash-generative global categories, personal hygiene and consumer health, that have high barriers to entry and rational pricing ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for $48.7bn. One of America’s ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling Palantir - whose stock has more than doubled this year on AI excitement and ...

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Kimberly-Clark Corp, the company behind popular brands like Kleenex and Huggies, has announced its plan to acquire Kenvue Inc ...